Cargando…

Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization

Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination approved for patients with cystic fibrosis (CF) who are homozygous for the F508del allele. This treatment showed significant clinical improvement; however, few studies have addressed the evolut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enaud, Raphael, Lussac-Sorton, Florian, Charpentier, Elena, Velo-Suárez, Lourdes, Guiraud, Jennifer, Bui, Stéphanie, Fayon, Michael, Schaeverbeke, Thierry, Nikolski, Macha, Burgel, Pierre-Régis, Héry-Arnaud, Geneviève, Delhaes, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100832/ https://www.ncbi.nlm.nih.gov/pubmed/36971560 http://dx.doi.org/10.1128/spectrum.02251-22

Ejemplares similares

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
por: Bui, Stéphanie, et al.
Publicado: (2021)

The gut-lung axis in the CFTR modulator era
por: Lussac-Sorton, Florian, et al.
Publicado: (2023)

New Insights in Microbial Species Predicting Lung Function Decline in CF: Lessons from the MucoFong Project
por: Francis, Florence, et al.
Publicado: (2021)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Nutritional impact of CFTR modulators in children with cystic fibrosis
por: Gaschignard, Margaux, et al.
Publicado: (2023)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
por: Colombo, C., et al.
Publicado: (2021)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
por: King, Susannah J., et al.
Publicado: (2021)

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis
por: Vadagam, Pratyusha, et al.
Publicado: (2018)

Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn’s-Like Microbiota Disturbances
por: Enaud, Raphaël, et al.
Publicado: (2019)

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
por: Kutney, Katherine, et al.
Publicado: (2019)

Interest of a Commercialized Pneumocystis jirovecii Quantitative PCR to Discriminate Colonization from Pneumocystis Pneumonia according to the Revised EORTC/MSGERC Criteria
por: Lussac-Sorton, Florian, et al.
Publicado: (2022)

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
por: Wark, Peter A. B., et al.
Publicado: (2019)

Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers
por: Garbuzenko, O.B., et al.
Publicado: (2019)

Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles
por: Chouchane, Ikrame, et al.
Publicado: (2019)

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor
por: Arnaud, François, et al.
Publicado: (2021)

How Clinically Efficient Is Lumacaftor/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review
por: Perveen, Sumera, et al.
Publicado: (2020)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

Gut bacteriobiota and mycobiota are both associated with Day-28 mortality among critically ill patients
por: Prevel, Renaud, et al.
Publicado: (2022)

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
por: Sharma, Dolly, et al.
Publicado: (2018)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
por: Choong, Eva, et al.
Publicado: (2022)

The short-term effects of ORKAMBI (lumacaftor/ivacaftor) on regional and distal lung structures using functional respiratory imaging
por: Lauwers, Eline, et al.
Publicado: (2021)

Lung Mycobiota α-Diversity Is Linked to Severity in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Enaud, Raphaël, et al.
Publicado: (2023)

The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis
por: Enaud, Raphaël, et al.
Publicado: (2018)

Profiling the response to lumacaftor‐ivacaftor in children with cystic between fibrosis and new insight from a French‐Italian real‐life cohort
por: Cornet, Matthieu, et al.
Publicado: (2022)

Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome
por: Pailhoriès, Hélène, et al.
Publicado: (2022)

Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis
por: Quon, Bradley S., et al.
Publicado: (2020)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
por: Wucherpfennig, Lena, et al.
Publicado: (2023)

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis
por: Soret, Perrine, et al.
Publicado: (2020)

A Case Report of Pulmonary Exacerbation after Initiation of Lumacaftor/Ivacaftor Therapy in a CF Female with Complicated Lung Disease
por: Hatziagorou, Elpis, et al.
Publicado: (2018)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0igfejv6s6p6aki8a6i2jifek4